The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2

Molecular Cell

Volumn 65, Issue 4, 2017, Pages 730-742.e5

  Hartwig, Torsten ^a   Montinaro, Antonella ^a   von Karstedt, Silvia ^a   Sevko, Alexandra ^a   Surinova, Silvia ^a   Chakravarthy, Ankur ^a   Taraborrelli, Lucia ^a   Draber, Peter ^a   Lafont, Elodie ^a   Arce Vargas, Frederick ^a   El Bahrawy, Mona A ^b   Quezada, Sergio A ^a   Walczak, Henning ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

CCL2; CCR2; cytokine; FADD; MDSC; microenvironment; TRAIL; TRAIL R; tumor

Indexed keywords

CASPASE 8; CHEMOKINE RECEPTOR CCR2; CXCL1 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; RAC1 PROTEIN; SECRETOME; TUMOR MARKER; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; CASP8 PROTEIN, HUMAN; CCL2 PROTEIN, HUMAN; CCR2 PROTEIN, HUMAN; CYTOKINE; FADD PROTEIN, HUMAN; TNFSF10 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CCL2 GENE; CELL KILLING; CELL POLARITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; GENE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INTRACELLULAR SIGNALING; LUNG ADENOCARCINOMA; MACROPHAGE; MONOCYTE; MOUSE; MYELOID-DERIVED SUPPRESSOR CELL; NONHUMAN; TRAIL GENE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; A-549 CELL LINE; ADENOCARCINOMA; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; GENETIC TRANSFECTION; GENETICS; HCT 116 CELL LINE; HELA CELL LINE; IMMUNOLOGY; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOLOGY; PHENOTYPE; RNA INTERFERENCE; SCID MOUSE; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR VOLUME;

A549 CELLS; ADENOCARCINOMA; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 8; CELL PROLIFERATION; CHEMOKINE CCL2; CYTOKINES; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; FEMALE; HCT116 CELLS; HELA CELLS; HUMANS; LUNG NEOPLASMS; MACROPHAGES; MICE, INBRED C57BL; MICE, SCID; PHENOTYPE; RECEPTORS, CCR2; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION; TUMOR BURDEN; TUMOR MICROENVIRONMENT;

EID: 85013218864     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2017.01.021     Document Type: Article

References (63)

1. Arenberg, D.A., Keane, M.P., DiGiovine, B., Kunkel, S.L., Strom, S.R., Burdick, M.D., Iannettoni, M.D., Strieter, R.M., Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines. Cancer Immunol. Immunother. 49 (2000), 63–70.
2. Ashkenazi, A., Pai, R.C., Fong, S., Leung, S., Lawrence, D.A., Marsters, S.A., Blackie, C., Chang, L., McMurtrey, A.E., Hebert, A., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104 (1999), 155–162.
3. Balkwill, F.R., Mantovani, A., Cancer-related inflammation: common themes and therapeutic opportunities. Semin. Cancer Biol. 22 (2012), 33–40.
4. Begley, L.A., Kasina, S., Mehra, R., Adsule, S., Admon, A.J., Lonigro, R.J., Chinnaiyan, A.M., Macoska, J.A., CXCL5 promotes prostate cancer progression. Neoplasia 10 (2008), 244–254.
5. Benjamini, Y., Hochberg, Y., Controlling the false discovery rate—a practical and powerful approach to multiple testing. J. Roy. Stat. Soc. B Met. 57 (1995), 289–300.
6. Bowman, B.M., Sebolt, K.A., Hoff, B.A., Boes, J.L., Daniels, D.L., Heist, K.A., Galbán, C.J., Patel, R.M., Zhang, J., Beer, D.G., et al. Phosphorylation of FADD by the kinase CK1α promotes KRASG12D-induced lung cancer. Sci. Signal., 8, 2015, ra9.
7. Cai, Z., Chen, Q., Chen, J., Lu, Y., Xiao, G., Wu, Z., Zhou, Q., Zhang, J., Monocyte chemotactic protein 1 promotes lung cancer-induced bone resorptive lesions in vivo. Neoplasia 11 (2009), 228–236.
8. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511 (2014), 543–550.
9. Chen, G., Bhojani, M.S., Heaford, A.C., Chang, D.C., Laxman, B., Thomas, D.G., Griffin, L.B., Yu, J., Coppola, J.M., Giordano, T.J., et al. Phosphorylated FADD induces NF-kappaB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. Proc. Natl. Acad. Sci. USA 102 (2005), 12507–12512.
10. Choi, M., Chang, C.Y., Clough, T., Broudy, D., Killeen, T., MacLean, B., Vitek, O., MSstats: an R package for statistical analysis of quantitative mass spectrometry-based proteomic experiments. Bioinformatics 30 (2014), 2524–2526.
11. Chun, E., Lavoie, S., Michaud, M., Gallini, C.A., Kim, J., Soucy, G., Odze, R., Glickman, J.N., Garrett, W.S., CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid-derived suppressor cell population and function. Cell Rep. 12 (2015), 244–257.
12. Cullen, S.P., Henry, C.M., Kearney, C.J., Logue, S.E., Feoktistova, M., Tynan, G.A., Lavelle, E.C., Leverkus, M., Martin, S.J., Fas/CD95-induced chemokines can serve as “find-me” signals for apoptotic cells. Mol. Cell 49 (2013), 1034–1048.
13. Dong, Y.L., Kabir, S.M., Lee, E.S., Son, D.S., CXCR2-driven ovarian cancer progression involves upregulation of proinflammatory chemokines by potentiating NF-κB activation via EGFR-transactivated Akt signaling. PLoS ONE, 8, 2013, e83789.
14. Ehlken, H., Krishna-Subramanian, S., Ochoa-Callejero, L., Kondylis, V., Nadi, N.E., Straub, B.K., Schirmacher, P., Walczak, H., Kollias, G., Pasparakis, M., Death receptor-independent FADD signalling triggers hepatitis and hepatocellular carcinoma in mice with liver parenchymal cell-specific NEMO knockout. Cell Death Differ. 21 (2014), 1721–1732.
15. El Khoury, J., Toft, M., Hickman, S.E., Means, T.K., Terada, K., Geula, C., Luster, A.D., Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 13 (2007), 432–438.
16. Fader, A.N., Rasool, N., Vaziri, S.A., Kozuki, T., Faber, P.W., Elson, P., Biscotti, C.V., Michener, C.M., Rose, P.G., Rojas-Espaillat, L., et al. CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes. Anticancer Res. 30 (2010), 4791–4798.
17. Fanger, N.A., Maliszewski, C.R., Schooley, K., Griffith, T.S., Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J. Exp. Med. 190 (1999), 1155–1164.
18. Fujita, M., Kohanbash, G., Fellows-Mayle, W., Hamilton, R.L., Komohara, Y., Decker, S.A., Ohlfest, J.R., Okada, H., COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res. 71 (2011), 2664–2674.
19. Gabrilovich, D.I., Nagaraj, S., Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9 (2009), 162–174.
20. Ganten, T.M., Koschny, R., Sykora, J., Schulze-Bergkamen, H., Buchler, P., Haas, T.L., Schader, M.B., Untergasser, A., Stremmel, W., Walczak, H., Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin. Cancer Res. 12 (2006), 2640–2646.
21. Griffith, T.S., Wiley, S.R., Kubin, M.Z., Sedger, L.M., Maliszewski, C.R., Fanger, N.A., Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J. Exp. Med. 189 (1999), 1343–1354.
22. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
23. Highfill, S.L., Cui, Y., Giles, A.J., Smith, J.P., Zhang, H., Morse, E., Kaplan, R.N., Mackall, C.L., Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci. Transl. Med., 6, 2014, 237ra67.
24. Hoesel, B., Schmid, J.A., The complexity of NF-κB signaling in inflammation and cancer. Mol. Cancer, 12, 2013, 86.
25. Hsu, H., Xiong, J., Goeddel, D.V., The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 81 (1995), 495–504.
26. Huang, W., Sherman, B.T., Lempicki, R.A., Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37 (2009), 1–13.
27. Johnstone, R.W., Frew, A.J., Smyth, M.J., The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer 8 (2008), 782–798.
28. Käll, L., Krogh, A., Sonnhammer, E.L., A combined transmembrane topology and signal peptide prediction method. J. Mol. Biol. 338 (2004), 1027–1036.
29. Kayagaki, N., Yamaguchi, N., Nakayama, M., Takeda, K., Akiba, H., Tsutsui, H., Okamura, H., Nakanishi, K., Okumura, K., Yagita, H., Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J. Immunol. 163 (1999), 1906–1913.
30. Lecis, D., De Cesare, M., Perego, P., Conti, A., Corna, E., Drago, C., Seneci, P., Walczak, H., Colombo, M.P., Delia, D., Sangaletti, S., Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity. Cell Death Dis., 4, 2013, e920.
31. Lemke, J., von Karstedt, S., Abd El Hay, M., Conti, A., Arce, F., Montinaro, A., Papenfuss, K., El-Bahrawy, M.A., Walczak, H., Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1. Cell Death Differ. 21 (2014), 491–502.
32. Lemke, J., von Karstedt, S., Zinngrebe, J., Walczak, H., Getting TRAIL back on track for cancer therapy. Cell Death Differ. 21 (2014), 1350–1364.
33. Lesokhin, A.M., Hohl, T.M., Kitano, S., Cortez, C., Hirschhorn-Cymerman, D., Avogadri, F., Rizzuto, G.A., Lazarus, J.J., Pamer, E.G., Houghton, A.N., et al. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res. 72 (2012), 876–886.
34. Li, X., Loberg, R., Liao, J., Ying, C., Snyder, L.A., Pienta, K.J., McCauley, L.K., A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res. 69 (2009), 1685–1692.
35. Luedde, T., Beraza, N., Kotsikoris, V., van Loo, G., Nenci, A., De Vos, R., Roskams, T., Trautwein, C., Pasparakis, M., Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11 (2007), 119–132.
36. MacLean, B., Tomazela, D.M., Shulman, N., Chambers, M., Finney, G.L., Frewen, B., Kern, R., Tabb, D.L., Liebler, D.C., MacCoss, M.J., Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26 (2010), 966–968.
37. Maeda, S., Kamata, H., Luo, J.L., Leffert, H., Karin, M., IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121 (2005), 977–990.
38. Mahoney, D.J., Cheung, H.H., Mrad, R.L., Plenchette, S., Simard, C., Enwere, E., Arora, V., Mak, T.W., Lacasse, E.C., Waring, J., Korneluk, R.G., Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc. Natl. Acad. Sci. USA 105 (2008), 11778–11783.
39. Mantovani, A., Sica, A., Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 22 (2010), 231–237.
40. Mantovani, A., Allavena, P., Sica, A., Balkwill, F., Cancer-related inflammation. Nature 454 (2008), 436–444.
41. Mariani, S.M., Krammer, P.H., Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells. Eur. J. Immunol. 28 (1998), 1492–1498.
42. Meylan, E., Dooley, A.L., Feldser, D.M., Shen, L., Turk, E., Ouyang, C., Jacks, T., Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 462 (2009), 104–107.
43. Mirandola, P., Ponti, C., Gobbi, G., Sponzilli, I., Vaccarezza, M., Cocco, L., Zauli, G., Secchiero, P., Manzoli, F.A., Vitale, M., Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. Blood 104 (2004), 2418–2424.
44. Naert, G., Rivest, S., A deficiency in CCR2+ monocytes: the hidden side of Alzheimer's disease. J. Mol. Cell Biol. 5 (2013), 284–293.
45. Newsom-Davis, T., Prieske, S., Walczak, H., Is TRAIL the holy grail of cancer therapy?. Apoptosis 14 (2009), 607–623.
46. Pobezinskaya, Y.L., Liu, Z., The role of TRADD in death receptor signaling. Cell Cycle 11 (2012), 871–876.
47. Qian, B.Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L.R., Kaiser, E.A., Snyder, L.A., Pollard, J.W., CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475 (2011), 222–225.
48. Rasamny, J.J., Allak, A., Krook, K.A., Jo, V.Y., Policarpio-Nicolas, M.L., Sumner, H.M., Moskaluk, C.A., Frierson, H.F. Jr., Jameson, M.J., Cyclin D1 and FADD as biomarkers in head and neck squamous cell carcinoma. Head Neck Surg. 146 (2012), 923–931.
49. Rivas-Fuentes, S., Salgado-Aguayo, A., Pertuz Belloso, S., Gorocica Rosete, P., Alvarado-Vásquez, N., Aquino-Jarquin, G., Role of chemokines in non-small cell lung cancer: angiogenesis and inflammation. J. Cancer 6 (2015), 938–952.
50. Roca, H., Varsos, Z.S., Sud, S., Craig, M.J., Ying, C., Pienta, K.J., CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J. Biol. Chem. 284 (2009), 34342–34354.
51. Scaffidi, C., Medema, J.P., Krammer, P.H., Peter, M.E., FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b. J. Biol. Chem. 272 (1997), 26953–26958.
52. Sevko, A., Umansky, V., Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves. J. Cancer 4 (2013), 3–11.
53. Sierra-Filardi, E., Nieto, C., Domínguez-Soto, A., Barroso, R., Sánchez-Mateos, P., Puig-Kroger, A., López-Bravo, M., Joven, J., Ardavín, C., Rodríguez-Fernández, J.L., et al. CCL2 shapes macrophage polarization by GM-CSF and M-CSF: identification of CCL2/CCR2-dependent gene expression profile. J. Immunol. 192 (2014), 3858–3867.
54. Singh, R.K., Lokeshwar, B.L., Depletion of intrinsic expression of interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs. Mol. Cancer, 8, 2009, 57.
55. Soria, G., Yaal-Hahoshen, N., Azenshtein, E., Shina, S., Leider-Trejo, L., Ryvo, L., Cohen-Hillel, E., Shtabsky, A., Ehrlich, M., Meshel, T., et al. Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions. Cytokine 44 (2008), 191–200.
56. Tang, W., Wang, W., Zhang, Y., Liu, S., Liu, Y., Zheng, D., TRAIL receptor mediates inflammatory cytokine release in an NF-kappaB-dependent manner. Cell Res. 19 (2009), 758–767.
57. Toh, B., Wang, X., Keeble, J., Sim, W.J., Khoo, K., Wong, W.C., Kato, M., Prevost-Blondel, A., Thiery, J.P., Abastado, J.P., Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol., 9, 2011, e1001162.
58. Trauzold, A., Siegmund, D., Schniewind, B., Sipos, B., Egberts, J., Zorenkov, D., Emme, D., Röder, C., Kalthoff, H., Wajant, H., TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 25 (2006), 7434–7439.
59. Varfolomeev, E., Maecker, H., Sharp, D., Lawrence, D., Renz, M., Vucic, D., Ashkenazi, A., Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J. Biol. Chem. 280 (2005), 40599–40608.
60. von Karstedt, S., Conti, A., Nobis, M., Montinaro, A., Hartwig, T., Lemke, J., Legler, K., Annewanter, F., Campbell, A.D., Taraborrelli, L., et al. Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis. Cancer Cell 27 (2015), 561–573.
61. Walczak, H., Miller, R.E., Ariail, K., Gliniak, B., Griffith, T.S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5 (1999), 157–163.
62. Wang, C., Deng, L., Hong, M., Akkaraju, G.R., Inoue, J., Chen, Z.J., TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412 (2001), 346–351.
63. Zhang, J., Lu, Y., Pienta, K.J., Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J. Natl. Cancer Inst. 102 (2010), 522–528.